ArticleNature biotechnology2011
Something new under the skin.
Article in Nature biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Silk Fibroin Microneedle Patches for the Sustained Release of Levonorgestrel.ACS applied bio materials · 2020Article
- Engineered biomaterials for cancer immunotherapy.MedComm · 2020Review
- Microneedle-Assisted Transdermal Delivery of Etanercept for Rheumatoid Arthritis Treatment.Pharmaceutics · 2019Article
- Polymeric microneedles for transdermal protein delivery.Advanced drug delivery reviews · 2018Review
- In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Evaluating the administration costs of biologic drugs: development of a cost algorithm.Health economics review · 2014Article
- High-level secretion of recombinant monomeric murine and human single-chain Fv antibodies from Drosophila S2 cells.Protein engineering, design & selection : PEDS · 2012Article
- Intranasal delivery to the brain.Nature biotechnology · 2011Article
- Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One-size-fits-all intravenous delivery of biologics may be giving way to alternate delivery routes that enable safer and more efficient drug administration. Michael Eisenstein reports.
Indexed as
Identifiers
21301430What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.